KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Capital Leases (2016)

Rigel Pharmaceuticals has reported Capital Leases over the past 4 years, most recently at $238000.0 for Q4 2016.

  • For Q4 2016, Capital Leases fell 93.12% year-over-year to $238000.0; the TTM value through Dec 2016 reached $238000.0, down 93.12%, while the annual FY2016 figure was $238000.0, 93.12% down from the prior year.
  • Capital Leases for Q4 2016 was $238000.0 at Rigel Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Over five years, Capital Leases peaked at $6.5 million in Q4 2014 and troughed at $238000.0 in Q4 2016.
  • A 3-year average of $3.4 million and a median of $3.5 million in 2015 define the central range for Capital Leases.
  • Biggest five-year swings in Capital Leases: tumbled 46.49% in 2015 and later crashed 93.12% in 2016.
  • Year by year, Capital Leases stood at $6.5 million in 2014, then crashed by 46.49% to $3.5 million in 2015, then crashed by 93.12% to $238000.0 in 2016.
  • Business Quant data shows Capital Leases for RIGL at $238000.0 in Q4 2016, $1.1 million in Q3 2016, and $1.9 million in Q2 2016.